当前位置: 首页 >> 检索结果
6403. Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection.
作者: Timothy A Bates.;Savannah K McBride.;Bradie Winders.;Devin Schoen.;Lydie Trautmann.;Marcel E Curlin.;Fikadu G Tafesse.
来源: JAMA. 2022年327卷2期179-181页
This study of fully vaccinated health care workers examines antibody levels and variant cross-neutralization after COVID-19 breakthrough infection.
6411. Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals.
作者: Brian Grunau.;David M Goldfarb.;Michael Asamoah-Boaheng.;Liam Golding.;Tracy L Kirkham.;Paul A Demers.;Pascal M Lavoie.
来源: JAMA. 2022年327卷3期279-281页
This study investigates the immunogenicity of extended mRNA vaccine dosing intervals.
6412. US State-Level Legal Interventions Related to COVID-19 Vaccine Mandates.
作者: Breanna Fernandes.;Mark Christopher Navin.;Dorit Rubinstein Reiss.;Saad B Omer.;Katie Attwell.
来源: JAMA. 2022年327卷2期178-179页
This study assesses state-level legal interventions to promote or impede COVID-19 vaccine mandates in the US since the beginning of the pandemic.
6413. Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older.
作者: Marie Joelle Jabagi.;Jérémie Botton.;Marion Bertrand.;Alain Weill.;Paddy Farrington.;Mahmoud Zureik.;Rosemary Dray-Spira.
来源: JAMA. 2022年327卷1期80-82页
This population-based study evaluates the short-term risk of severe cardiovascular events among French residents aged 75 years or older after receipt of the BNT162b2 mRNA COVID-19 vaccination.
|